US › Healthcare

Aquestive Therapeutics Inc (AQST)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$3.61-1.37%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue

$7.6M

Revenue YoY

-41.0%

Net profit

$-16.5M

EPS

$-0.13

EPS estimate

$-0.10

Net margin

-218.3%

EPS came in at -0.13 against a street estimate of -0.10 — a miss of 30.0%.

Key statistics

Market cap

$476.9M

Forward P/E

0.0

P/B

14.15

Book value

$-0.28

EPS (TTM)

$-0.66

52-week high

$6.74

52-week low

$2.93

50-day MA

$4.62

200-day MA

$4.21

Beta

1.50

Analyst view

Analysts rate Aquestive Therapeutics Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $9.33.

Shareholding

Insiders

10.79%

Institutions

57.95%

Largest institutional holders

Fund	Stake
Bratton Capital Management, L.P.	7.82%
BlackRock Inc	6.43%
RTW INVESTMENTS, LLC	5.92%
Vanguard Capital Management, LLC	3.65%
Federated Hermes Inc	2.48%
State Street Corp	2.33%
Geode Capital Management, LLC	2.09%
Samsara BioCapital, LLC	1.99%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aquestive Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.